UNSPSC 51393602: Protokylol

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C18H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y5Y4EEO2V, chemically known as 1-(3,4-dihydroxyphenyl)-2-(alpha-methyl-3,4-methylendioxyphenethylamino)ethanol but generally known as protokylol, which bears US NIH Compound Identifier 4969. European Medicines Agency schedules Protokylol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10144MIG.

UNSPSC 51393602 Protokylol is a Commodity code that covers naloxone and pharmaceutical drug deactivation products procured by state and local health agencies. State and local governments buy naloxone (an opioid antagonist) and safe drug deactivation systems under this code, typically in bulk quantities to support community health and emergency response initiatives. Issuing bodies include county health departments and state health and human services commissions pursuing both direct product purchases and capability assessments for pharmacy benefit programs. The scope of work ranges from straightforward commodity procurement of naloxone units and deactivation systems with quarterly delivery schedules to exploratory vendor engagement around direct-to-manufacturer prescription fulfillment models and pharmacy benefit program redesign.

Recent activity centers on Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to its Community Health Building, with bidders required to include all shipping and delivery costs in their proposals and comply with drug-free workplace certification and E-Verify requirements; the contract carries a two-year initial term with one-year renewal option and includes potential FEMA funding with associated federal compliance obligations. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about vendors' experience with direct contracting for self-insured employers and health plans, flexible pricing models, and value-based agreement implementation—this exploratory phase will inform a subsequent formal RFP with established financial and temporal parameters.